Revisiting the outcome of adult wild-type Htt inactivation in the context of HTT -lowering strategies for Huntington's disease.
Sara RegioGabriel VacheyEnrique GoñiFabio DuarteMargareta RybarikovaMélanie SipionMaria ReyMaite HuarteNicole DéglonPublished in: Brain communications (2023)
Huntingtin-lowering strategies are central to therapeutic approaches for Huntington's disease. Recent studies reported the induction of age- and cell type-specific phenotypes by conditional huntingtin knockout, but these experimental conditions did not precisely mimic huntingtin-lowering or gene-editing conditions in terms of the cells targeted and brain distribution, and no transcriptional profiles were provided. Here, we used the adeno-associated delivery system commonly used in CNS gene therapy programmes and the self-inactivating KamiCas9 gene-editing system to investigate the long-term consequences of wild-type mouse huntingtin inactivation in adult neurons and, thus, the feasibility and safety of huntingtin inactivation in these cells. Behavioural and neuropathological analyses and single-nuclei RNA sequencing indicated that huntingtin editing in 77% of striatal neurons and 16% of cortical projecting neurons in adult mice induced no behavioural deficits or cellular toxicity. Single-nuclei RNA sequencing in 11.5-month-old animals showed that huntingtin inactivation did not alter striatal-cell profiles or proportions. Few differentially expressed genes were identified and Augur analysis confirmed an extremely limited response to huntingtin inactivation in all cell types. Our results therefore indicate that wild-type huntingtin inactivation in adult striatal and projection neurons is well tolerated in the long term.
Keyphrases
- wild type
- single cell
- gene therapy
- induced apoptosis
- spinal cord
- parkinson disease
- functional connectivity
- cell therapy
- crispr cas
- traumatic brain injury
- computed tomography
- genome wide
- young adults
- stem cells
- cell cycle arrest
- gene expression
- adipose tissue
- metabolic syndrome
- dna methylation
- multiple sclerosis
- mesenchymal stem cells
- magnetic resonance imaging
- cell proliferation
- transcription factor
- skeletal muscle
- cancer therapy
- brain injury
- blood brain barrier
- spinal cord injury
- drug induced
- subarachnoid hemorrhage
- high glucose
- insulin resistance
- cerebral ischemia